Compliance, as a flow.
What a buyer commissioning their first branded medicine actually does — and where the law stops being a PDF and becomes a step they cannot skip.
Two product states, not two audiences.
The top-level split of the whole product. Both routes end in a verified factory; they differ in whether the thing already exists.
It already exists
- Finished, batch-tested stock in a verified factory.
- Batch number and expiry shown, because for ready stock those decide the purchase.
- No minimum order quantity.
Delivered orders complete themselves. A short flow for a short decision.
It does not exist yet
- Commission manufacturing under your own label.
- Manufacturers compared side by side on price, minimum order, lead time, certifications and rating.
- Packaging specified and the order negotiated before it is made.
Where all the complexity lives.
From sign-up to a contestable rating.
Verified, before anything else
Tax registration checked live against the government registry with the business address auto-filled, then one combined drug-licence upload. Browsing and carting are allowed while review is pending; submitting an inquiry is not — the gate sits at the point of commitment rather than at the door.
Compare 214 products and their makers
Search by molecule or brand. Only approved, verified factories are visible at all, and every one of them is compared on the same five attributes.
Specify the packaging
Four steps covering container, surface and outer — with the mandatory-label checklist inside the flow.
Raise the inquiry at the live rate
Never a stored one. There is no buyer-side price lock-in: a factory can never be held to a rate it has since moved off, and the interface discloses the trade-off.
Negotiate in the Deal Room
Chat and files scoped to one inquiry, with live price revision that recalculates fee, total and invoice automatically and writes every change to an audit trail.
Pay, produce, deliver, rate
A fixed pipeline both sides can see, ending in mutual one-to-five ratings that either party may contest.
Specifying a medicine's packaging, without knowing the vocabulary.
A brand owner commissioning their first product does not know why a shrink band matters. Each factory configures what it can supply; the wizard turns that into illustrated choices with a running summary.
| Parameter | Options | The design decision |
|---|---|---|
| Bottle type and shape | Clear plastic, opaque, glass, airless pump, squeeze, flip-top — round, oval, square, hexagonal or custom. | Shown as product-quality photographs on white, supplied by the factory itself. |
| Measuring cap | Yes or no. | Shown only for liquid formulations, because it is meaningless otherwise. |
| Label material and finish | Paper or water-resistant film; glossy, matte or embossed. | The difference is explained in the choice rather than assumed. |
| Carton | None, plain, or printed. | Choosing printed means carton artwork as well as a bottle label — and the wizard says so at the moment of choosing. |
| Tablets and capsules | Blister and strip formats, with count per strip and strips per box. | A separate branch entirely. A wizard that asked a tablet buyer about bottle shape would be a form, not a product. |
The regulation is a step in the wizard.
- Before
- Indian law fixes eighteen elements that must appear on a pharmaceutical label. The obvious implementation links to a PDF.
- What forced it
- A buyer discovering a mandatory element at artwork rejection has already paid a designer for the wrong file.
- The decision
- The list sits inside the artwork step as checkboxes the buyer cannot advance past. It is centrally maintained and no user can shorten or modify it.
- What it changed
- Honestly framed as a self-declaration, not verification — the factory and a reviewer check the actual artwork afterwards. Its job is to make a buyer read the requirements while they are still designing the label.
Not having artwork yet is a modelled state.
- Before
- A buyer is usually ready to commit before their label artwork is finished.
- What forced it
- A flow that demands the file would stall the order at its most fragile moment.
- The decision
- The buyer selects “artwork to be provided later”. The inquiry is marked pending artwork, and the factory will not begin production until artwork arrives and is approved.
- What it changed
- The order progresses while the production gate holds — and the wizard deep-links to the firm's packaging consultation, handing the buyer to the practice at the moment they need advice rather than a price.
Negotiation, with the arithmetic attached.
In this trade a negotiation happens over calls and messages, and the paperwork is reconstructed afterwards from memory. This inverts that: the conversation and the document are the same object.
- A private room scoped to one inquiry, with threaded chat and file exchange for specifications and artwork.
- Live price revision, with fee, total and invoice recalculated automatically — nothing re-entered by hand.
- Every change written to an audit trail, and the invoice locked once payment is made.
- A fixed pipeline visible to both sides, with rejection requiring a stated reason and a daily job that flags stale deals but never auto-rejects.
- Mutual one-to-five ratings that either side can contest, so a factory whose reputation keeps it on the platform has a route to challenge an unfair one.
- No screenshot of any authenticated interior appears in this study — the interiors were never captured, and mocking them up would look like evidence while being an illustration.
- No usability finding is claimed, because no usability testing is documented.
- The bulk-upload template flattens packaging options into free text rather than a strict list, because the underlying data model is itself free-form — a deliberate choice to match existing data, recorded as such.
The full product study, panel by panel.
Ten rendered panels covering the two ways to buy, the full journey, every wizard parameter, the eighteen mandatory label elements, the Deal Room, the pipeline and the stated limits.